CN110294804B - 针对β淀粉样蛋白的抗体 - Google Patents

针对β淀粉样蛋白的抗体 Download PDF

Info

Publication number
CN110294804B
CN110294804B CN201910295599.9A CN201910295599A CN110294804B CN 110294804 B CN110294804 B CN 110294804B CN 201910295599 A CN201910295599 A CN 201910295599A CN 110294804 B CN110294804 B CN 110294804B
Authority
CN
China
Prior art keywords
antibody
binding
amino acid
peptide
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910295599.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110294804A (zh
Inventor
M·格罗夫斯
S·古斯塔夫松
K·豪格伦德
D·罗恩
C·劳埃德
A·尼克森
C·尼瓦
S·西蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110294804(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to CN201910295599.9A priority Critical patent/CN110294804B/zh
Publication of CN110294804A publication Critical patent/CN110294804A/zh
Application granted granted Critical
Publication of CN110294804B publication Critical patent/CN110294804B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201910295599.9A 2012-10-15 2013-10-15 针对β淀粉样蛋白的抗体 Active CN110294804B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910295599.9A CN110294804B (zh) 2012-10-15 2013-10-15 针对β淀粉样蛋白的抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261713996P 2012-10-15 2012-10-15
US61/713,996 2012-10-15
PCT/EP2013/071567 WO2014060444A1 (en) 2012-10-15 2013-10-15 Antibodies to amyloid beta
CN201380053909.7A CN105164156B (zh) 2012-10-15 2013-10-15 针对β淀粉样蛋白的抗体
CN201910295599.9A CN110294804B (zh) 2012-10-15 2013-10-15 针对β淀粉样蛋白的抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380053909.7A Division CN105164156B (zh) 2012-10-15 2013-10-15 针对β淀粉样蛋白的抗体

Publications (2)

Publication Number Publication Date
CN110294804A CN110294804A (zh) 2019-10-01
CN110294804B true CN110294804B (zh) 2023-07-14

Family

ID=49765450

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910295599.9A Active CN110294804B (zh) 2012-10-15 2013-10-15 针对β淀粉样蛋白的抗体
CN201380053909.7A Active CN105164156B (zh) 2012-10-15 2013-10-15 针对β淀粉样蛋白的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380053909.7A Active CN105164156B (zh) 2012-10-15 2013-10-15 针对β淀粉样蛋白的抗体

Country Status (23)

Country Link
US (6) US9834598B2 (https=)
EP (2) EP3721942A1 (https=)
JP (5) JP6343615B2 (https=)
KR (2) KR102308915B1 (https=)
CN (2) CN110294804B (https=)
AU (3) AU2013333948B2 (https=)
BR (1) BR112015008347B1 (https=)
CA (1) CA2888322A1 (https=)
CY (1) CY1122987T1 (https=)
DK (1) DK2906597T3 (https=)
ES (1) ES2802873T3 (https=)
HR (1) HRP20200936T1 (https=)
HU (1) HUE051127T2 (https=)
LT (1) LT2906597T (https=)
ME (1) ME03751B (https=)
MX (2) MX370725B (https=)
PL (1) PL2906597T3 (https=)
PT (1) PT2906597T (https=)
RS (1) RS60388B1 (https=)
RU (2) RU2651486C2 (https=)
SI (1) SI2906597T1 (https=)
SM (1) SMT202000340T1 (https=)
WO (1) WO2014060444A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000340T1 (it) * 2012-10-15 2020-07-08 Medimmune Ltd Anticorpi contro il beta amiloide
US10654917B2 (en) 2015-01-29 2020-05-19 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
EP3368561B1 (en) 2015-10-30 2025-09-17 Medimmune Limited Prevention of n-terminal truncation in igg light chains
WO2017158064A1 (en) 2016-03-15 2017-09-21 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
CN114796481A (zh) * 2016-06-07 2022-07-29 生物基因国际神经科学有限责任公司 治疗阿尔茨海默病的方法
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN111094340B (zh) 2018-07-17 2022-11-22 江苏恒瑞医药股份有限公司 抗Abeta抗体、其抗原结合片段及应用
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
CN115175932B (zh) * 2019-07-16 2025-10-31 赛诺菲 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
CN111454980A (zh) * 2020-04-14 2020-07-28 郑州师范学院 重组载体的构建方法及其构建的重组载体及应用
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2021260193A1 (en) 2020-06-25 2021-12-30 Medimmune Limited Prevention of axonal damage using antibody binding to amyloid beta 1-42
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
KR102565470B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 sma_04088-2 및 이를 포함하는 알츠하이머병 치료용 조성물
KR102565471B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 cbrv1-04369 및 이를 포함하는 알츠하이머병 치료용 조성물
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
CN116716351B (zh) * 2023-03-30 2024-02-23 湖北天勤生物技术研究院有限公司 用于构建食蟹猴阿尔兹海默症模型的组合物及其应用和构建方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646559A (zh) * 2002-04-19 2005-07-27 多伦多大学懂事局 治疗阿尔茨海默氏病的免疫学方法及组合物
WO2006103116A1 (en) * 2005-04-01 2006-10-05 Biotherapix Molecular Medicines S.L.U. Human antibodies with beta-amyloid peptide-binding capacity and their applications
WO2009080816A1 (en) * 2007-12-21 2009-07-02 Altonabiotec Ag Fusion polypeptides comprising a shbg dimerization component and uses thereof
CN101611057A (zh) * 2006-06-23 2009-12-23 阿斯特拉捷利康股份公司 人il-17的抗体分子
CN102307901A (zh) * 2008-11-07 2012-01-04 米迪缪尼有限公司 抗il-1r1结合成员

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565332A (en) 1896-08-04 Toy for making soap-bubbles
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5185243A (en) 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
CA2402452A1 (en) 2000-03-31 2001-10-11 Cambridge Antibody Technology Limited Improvements to ribosome display
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
WO2003015691A2 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
US7807157B2 (en) * 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
US7871782B2 (en) * 2004-03-29 2011-01-18 The University Court Of The University Of Aberdeen Specific binding members against synaptophysin
CA2576405A1 (en) * 2004-08-11 2006-02-16 Mitsubishi Chemical Corporation Antibody and utilization of the same
CN101076543A (zh) * 2004-10-13 2007-11-21 阿布林克斯公司 用于治疗和诊断变性神经疾病如阿尔茨海默症的单结构域骆驼抗淀粉样蛋白β的抗体以及包含它的多肽
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
GB0500099D0 (en) 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
EP2224000B1 (en) * 2007-10-29 2020-05-13 TAO Health Life Pharma Co., Ltd. Antibody and use thereof
US20100323375A1 (en) * 2007-12-12 2010-12-23 Immuno-Biological Laboratories Co., Ltd. Agent and method for diagnosis on the occurrence of alzheimer's disease or the tendency to develop alzheimer's disease
EP2235058A2 (en) * 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid antibodies and uses thereof
SMT202000340T1 (it) * 2012-10-15 2020-07-08 Medimmune Ltd Anticorpi contro il beta amiloide
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
AR107783A1 (es) 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
WO2017158064A1 (en) 2016-03-15 2017-09-21 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646559A (zh) * 2002-04-19 2005-07-27 多伦多大学懂事局 治疗阿尔茨海默氏病的免疫学方法及组合物
WO2006103116A1 (en) * 2005-04-01 2006-10-05 Biotherapix Molecular Medicines S.L.U. Human antibodies with beta-amyloid peptide-binding capacity and their applications
CN101611057A (zh) * 2006-06-23 2009-12-23 阿斯特拉捷利康股份公司 人il-17的抗体分子
WO2009080816A1 (en) * 2007-12-21 2009-07-02 Altonabiotec Ag Fusion polypeptides comprising a shbg dimerization component and uses thereof
CN102307901A (zh) * 2008-11-07 2012-01-04 米迪缪尼有限公司 抗il-1r1结合成员

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
靶向β淀粉样蛋白的阿尔茨海默病疫苗研究进展;徐青;余云舟;赵萌;;生物技术通讯(第02期);第273-276页 *

Also Published As

Publication number Publication date
AU2018256498B2 (en) 2020-07-23
AU2020256414B2 (en) 2024-01-25
CN110294804A (zh) 2019-10-01
ES2802873T3 (es) 2021-01-21
US12098191B2 (en) 2024-09-24
HUE051127T2 (hu) 2021-03-01
AU2018256498C1 (en) 2024-06-20
RU2018110064A (ru) 2019-02-28
US11286297B2 (en) 2022-03-29
KR20210125587A (ko) 2021-10-18
HRP20200936T1 (hr) 2020-09-18
MX370725B (es) 2019-12-20
AU2020256414A1 (en) 2020-11-12
HK1213906A1 (en) 2016-07-15
MX2019015602A (es) 2020-02-26
JP2020099340A (ja) 2020-07-02
ME03751B (me) 2021-04-20
CA2888322A1 (en) 2014-04-24
US10662239B2 (en) 2020-05-26
US20210009665A1 (en) 2021-01-14
KR102308915B1 (ko) 2021-10-06
EP3721942A1 (en) 2020-10-14
EP2906597A1 (en) 2015-08-19
JP2022025078A (ja) 2022-02-09
PL2906597T3 (pl) 2020-09-21
RU2651486C2 (ru) 2018-04-19
RS60388B1 (sr) 2020-07-31
US12344664B2 (en) 2025-07-01
CN105164156A (zh) 2015-12-16
JP7301924B2 (ja) 2023-07-03
CN105164156B (zh) 2019-04-02
KR102450670B1 (ko) 2022-10-04
RU2689674C2 (ru) 2019-05-28
AU2013333948B2 (en) 2018-08-02
US9834598B2 (en) 2017-12-05
US20240294619A1 (en) 2024-09-05
RU2018110064A3 (https=) 2019-02-28
BR112015008347B1 (pt) 2023-12-26
JP6959377B2 (ja) 2021-11-02
AU2013333948A1 (en) 2015-05-14
EP2906597B1 (en) 2020-04-08
MX2015004763A (es) 2016-01-08
SI2906597T1 (sl) 2020-08-31
WO2014060444A1 (en) 2014-04-24
JP2023116770A (ja) 2023-08-22
JP2018150346A (ja) 2018-09-27
KR20150066593A (ko) 2015-06-16
US20250304670A1 (en) 2025-10-02
JP2015536645A (ja) 2015-12-24
DK2906597T3 (da) 2020-07-13
LT2906597T (lt) 2020-07-10
AU2018256498A1 (en) 2018-11-22
US20180105585A1 (en) 2018-04-19
PT2906597T (pt) 2020-06-18
JP6669805B2 (ja) 2020-03-18
SMT202000340T1 (it) 2020-07-08
BR112015008347A2 (pt) 2017-12-05
US20150299299A1 (en) 2015-10-22
US20220251181A1 (en) 2022-08-11
RU2015118180A (ru) 2016-12-10
CY1122987T1 (el) 2021-10-29
JP6343615B2 (ja) 2018-06-20

Similar Documents

Publication Publication Date Title
JP7301924B2 (ja) アミロイドβに対する抗体
JP2019511500A (ja) アミロイドベータの蓄積に関連する障害の処置のためのｂａｃｅ阻害剤と抗体または抗原結合性断片との組合せ
HK40014502B (en) Antibodies to amyloid beta
HK40014502A (en) Antibodies to amyloid beta
HK1213906B (en) Antibodies to amyloid beta
BR122023019806B1 (pt) Molécula de anticorpo, uso de dita molécula de anticorpo, composição para uso no tratamento de uma doença associada com betaamilóide, uso de uma composição, ácido nucleico, célula hospedeira e método para produção de uma molécula de anticorpo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014502

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20331224

TG01 Patent term adjustment